# HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction

> **NCT05095467** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Xuefei.Wang** · enrollment: 157 (estimated)

## Conditions studied

- Stomach Neoplasms
- Peritoneal Metastases

## Interventions

- **PROCEDURE:** HIPEC
- **DRUG:** Paclitaxel-albumin
- **DRUG:** Tegafur-gimeracil-oteracil potassium
- **PROCEDURE:** Surgery+HIPEC

## Key facts

- **NCT ID:** NCT05095467
- **Lead sponsor:** Xuefei.Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2021-10
- **Primary completion:** 2023-10
- **Final completion:** 2026-10
- **Target enrollment:** 157 (ESTIMATED)
- **Last updated:** 2021-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05095467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05095467, "HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05095467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*